CLDN18.2

Close
Menu

Reporting test results

Learn how to accurately and consistently report CLDN18.2 expression

Both membranous stain intensity and percentage of tumour cells stained are critical for CLDN18.2 reporting1

In addition to membranous stain intensity and percentage of tumour cells stained, it is recommended that the biomarker report also includes

Integrated reporting:

  • The type of testing method used
  • A description of the status of the sample, such as “positive,” “negative,” or “inconclusive”
  • Any relevant notes or observations regarding the sample or results
overlayvideoimage
play-icon

reportingtestresults

reportingtestresults

closeicon
volumeicon

reportingtestresults

closeicon

reportingtestresults

transcript

How to Report CLDN18.2

Kristina A. Matkowskyj, MD, PhD

Consistent, integrated reporting of biomarkers can inform clinical decision making and patient care2

 

Integrated biomarker reporting:

  • Gives the HCP the ability to review biomarker test results that inform clinical approach 
  • Can be used as a tool to help pathologists educate the multidisciplinary team

 

Explore CLDN18.2 resources
Pathologists play a critical role in driving consistent, integrated reporting that can help multidisciplinary teams develop the most effective treatment plans for their patients

References: 1. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med (Epub) 10-26-2021. 2. Warner JL, Jain SK, Levy MA. Integrating cancer genomic data into electronic health records. Genome Medicine 2016;8(113).